AMAlyssa Macchiaroli
Alyssa Macchiaroli
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alyssa Macchiaroli has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Akhilesh Mishra
Department of Life Science, National Institute of Technology Rourkela
36 shared publications - Alana Christie
O’Donnell-SPH- Biostatistics Shared Resource, The University of Texas Southwestern Medical Center, Dallas, USA
36 shared publications - Alexander Ivanishev
Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas
36 shared publications - Allison Joyce
Los Angeles County Department of Public Health, Acute Communicable Diseases Control Program , Los Angeles, California
36 shared publications - Christina Stevens
Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas
36 shared publications - Daniel Li
Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas
36 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans